MedTrace Logo

Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions

NCT07691268 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-07-08

No results posted yet for this study

Summary

Phase 1 study to evaluate the safety and the pharmacokinetics of "UI111" and "UIC202006" in healthy adult volunteers under fed state conditions

\- Open-label, randomized, single-dose, 2-sequence, 4-period, crossover design

Conditions

Interventions

DRUG

Administration of UI111

1cap, once a day

DRUG

Administration of UIC202006

1cap, once a day

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-13
Primary Completion
2025-03-10
Completion
2025-03-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07691268 on ClinicalTrials.gov